系统评价转移性 Merkel 细胞癌患者化疗方案的疗效、安全性和耐受性结果的文献综述。
Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma.
机构信息
Division of Dermatology, University of Washington Medical School, Fred Hutchinson Cancer Research Center, Seattle, WA 98195-8050, USA.
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.
出版信息
Future Oncol. 2017 Jun;13(14):1263-1279. doi: 10.2217/fon-2017-0072. Epub 2017 Mar 28.
AIM
Merkel cell carcinoma (MCC) is a rare neuroendocrine, cutaneous malignancy with poor prognosis once metastasized. The aim of this study was to conduct a systematic literature review to assess clinical outcomes associated with chemotherapy regimens in metastatic MCC.
MATERIALS & METHODS: Embase, MEDLINE, MEDLINE-In-Process and CENTRAL were searched for studies published in January 2016.
RESULTS & CONCLUSION: Overall, the literature on chemotherapy in patients with metastatic MCC is sparse, with most studies being case series/reports. Across all studies, response rates ranged from 20 to 61%, with higher response rates in first-line setting (53-61%) versus second-line setting (23-45%). Among responders, duration of response was short (≤8 months) in both first- and second-line settings. There is a need for novel agents that can induce durable responses in metastatic MCC.
目的
默克尔细胞癌（MCC）是一种罕见的神经内分泌、皮肤恶性肿瘤，一旦转移预后不良。本研究旨在进行系统文献回顾，评估转移性 MCC 化疗方案的临床结局。
材料与方法
检索 2016 年 1 月发表的 Embase、MEDLINE、MEDLINE-In-Process 和 CENTRAL 中的研究。
结果与结论
总体而言，转移性 MCC 化疗的文献很少，大多数研究为病例系列/报告。在所有研究中，缓解率为 20%至 61%，一线治疗（53%至 61%）的缓解率高于二线治疗（23%至 45%）。在有反应的患者中，一线和二线治疗的缓解持续时间都较短（≤8 个月）。需要新型药物来诱导转移性 MCC 的持久缓解。
Zotero 插件